

Title (en)  
COMPOUNDS AND METHODS

Title (de)  
ZUSAMMENSTELLUNGEN UND METHODEN

Title (fr)  
COMPOSES ET PROCEDES

Publication  
**EP 1313477 A1 20030528 (EN)**

Application  
**EP 01958995 A 20010713**

Priority  
• US 0122529 W 20010713  
• US 21850500 P 20000715

Abstract (en)  
[origin: WO0205819A1] This invention relates to substituted heterocyclic compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, by the use of substituted heterocyclic compounds which are CCR5 receptor antagonists. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

IPC 1-7  
**A61K 31/495**; **A61K 31/4418**; **A61P 11/06**; **A61P 19/02**; **C07D 211/70**; **C07D 295/20**; **C07D 213/74**; **C07D 209/40**; **C07D 417/04**; **C07D 417/14**; **C07D 401/04**; **C07D 401/14**; **C07D 277/82**; **C07D 241/20**; **C07D 211/26**

IPC 8 full level  
**C07D 209/08** (2006.01); **C07D 209/40** (2006.01); **C07D 211/22** (2006.01); **C07D 211/26** (2006.01); **C07D 211/32** (2006.01); **C07D 211/52** (2006.01); **C07D 211/64** (2006.01); **C07D 211/70** (2006.01); **C07D 213/74** (2006.01); **C07D 215/38** (2006.01); **C07D 241/20** (2006.01); **C07D 277/82** (2006.01); **C07D 401/12** (2006.01); **C07D 401/14** (2006.01); **C07D 409/12** (2006.01); **C07D 417/14** (2006.01); **C07D 491/10** (2006.01)

CPC (source: EP)  
**A61P 11/06** (2017.12); **A61P 19/02** (2017.12); **C07D 209/08** (2013.01); **C07D 209/40** (2013.01); **C07D 211/22** (2013.01); **C07D 211/26** (2013.01); **C07D 211/32** (2013.01); **C07D 211/52** (2013.01); **C07D 211/64** (2013.01); **C07D 211/70** (2013.01); **C07D 213/74** (2013.01); **C07D 215/38** (2013.01); **C07D 241/20** (2013.01); **C07D 277/82** (2013.01); **C07D 401/12** (2013.01); **C07D 401/14** (2013.01); **C07D 409/12** (2013.01); **C07D 417/14** (2013.01); **C07D 491/10** (2013.01)

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0205819 A1 20020124**; AU 8059901 A 20020130; EP 1313477 A1 20030528; EP 1313477 A4 20040303

DOCDB simple family (application)  
**US 0122529 W 20010713**; AU 8059901 A 20010713; EP 01958995 A 20010713